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Abstract
Human CD93 is a heavily O-glycosylated type I transmembrane protein consisting of unique C-type
lectin domains (CTLDs) containing glycoprotein. CD93 is mainly expressed on myeloid cells
(monocytes and granulocytes) and endothelial cells. However, the expression patterns of CD93 on
various other kinds of cells are not well understood. In this study, we found that CD93 was recognized
by a CD93 monoclonal antibody (mAb) (mNI-11) that was established in our laboratories and was
expressed on a broad hematopoietic stem cell population (CD34+ cells) from human neonatal umbilical
cord blood cells (UCBCs), as shown using a two-color flow cytometric analysis. In addition, the CD93
recognized by mNI-11 was also expressed on a narrow hematopoietic stem cell population
(CD34+CD45dim+ cells) in which the non-specific reactivity of CD34 mAb from human neonatal UCBCs
was excluded using a three-color flow cytometric analysis. Taken together, these results provide the
first evidence concerning the identification of CD93 expression on hematopoietic stem cells. These cell
populations (CD34+CD93+ and CD34+CD45dim+CD93+ cells) in human neonatal UCBCs are thought to
have an important role in cell biology, transplantation, and immature/mature immune responses.
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Introduction
Human CD93 has a molecular weight of about 100 -
kDa. CD93 belongs to the Group XIV family of
transmembrane glycoproteins. This molecule is a heavily
O-glycosylated type I transmembrane protein consisting of
C-type lectin-like domains (CTLDs) containing
glycoprotein, followed by a series of epidermal growth
factor (EGF)-like repeats.１) Although CD93 was previously
identified as a receptor for complement component 1,
subcomponent q phagocytosis (C1qRp) that interacts
with defense collagens such as C1q, mannose-binding
lectin (MBL), and pulmonary surfactant protein A (PS-A)
and is involved in the C1q-mediated enhancement of
phagocytosis for various antigens,２, ３) several recent
studies have reported that CD93 is not a C1q receptor
involved in the C1q-mediated enhancement of phagocytosis
against various antigens and the clearance of apoptotic
cells.４, ５) However, the detailed immunological functions of
CD93 remain uncertain. 
On the other hand, CD93 is mainly expressed on
myeloid cells (monocytes and granulocytes) and
endothelial cells.５) CD93 is strongly upregulated after the
exposure of human monocyte-like cell line (U937) to a
protein kinase C (PKC) activator, phorbol myristate
acetate (PMA), and this upregulation is controlled by a
PKC delta isoenzyme inhibitor, Rottlelin.６) However, the
pattern and regulation of CD93 expression on various
kinds of cells other than those with a myeloid cell
lineage, especially hematopoietic stem cells possessing
multipotent activities in immune responses, are not well
understood.
In this study, we focused on CD93 expression in
broad and narrow human hematopoietic stem cell
populations (CD34+ and CD34+CD45dim+ cells) and
investigated the expression patterns of CD93 on these
cell populations in human neonatal umbilical cord blood
cells (UCBCs) using a CD93 monoclonal antibody (mAb)
(mNI-11) established in our laboratories and flow
cytometry to define the expression pattern on immature
multipotent hematopoietic stem cells. 
Materials and Methods
Donors and preparation of peripheral blood mononuclear
cells from normal adults and umbilical cord blood cells
from neonates
We prepared human peripheral blood mononuclear cells
(PBMCs) from four normal adults and human neonatal
umbilical cord blood cells (UCBCs) from the umbilical
veins of 17 neonates according to a previously described
methodology.７) Informed consent was obtained from all the
donors/parents. 
Antibodies
A phycoerythrin (PE)-conjugated CD93 monoclonal
antibody (mAb) (mNI-11) (mouse IgG1) ８) was established
in our laboratories. Fluorescein isothiocyanate (FITC)-
conjugated CD34 mAb (My10) (mouse IgG1),
allophycocyanin (APC)-conjugated CD34 mAb (My10)
(mouse IgG1), and peridinin chlorophyll protein (PerCP)-
conjugated CD45 mAb (2D1) (mouse IgG1) were
purchased from BD Biosciences Co. (USA). Isotype-
matched normal mouse IgG1 was purchased from MBL
Co. (Nagoya, Japan). 
Flow cytometry
The cells were washed in cold phosphate-buffered saline
(PBS) containing 0.1% NaN3 (subsequently referred to as the
washing buffer) and were then incubated in PBS containing
25% normal goat serum, 1 mg/mL of normal human IgG,
and 0.1% NaN3 for 10 min on ice to block the Fc receptor of
IgG. The cells were then incubated with an optimal
concentration of PE-conjugated CD93 (mAb) (mNI-11) and
FITC-conjugated CD34 mAb (My10) for 40 min at room
temperature. In some experiments, the cells were then
incubated with an optimal concentration of APC-conjugated
CD34 mAb (My10), PerCP-conjugated CD45 mAb (2D1),
and PE-conjugated CD93 (mAb) (mNI-11) for 40 min at
room temperature. Negative controls were provided by
incubation with isotype-matched normal mouse IgG1
under the same conditions. Following a final wash with the
washing buffer and resuspension in PBS containing 2%
fetal calf serum (FCS) and 0.1% NaN3, the cellular debris
and aggregates were excluded. The percentages of
positively stained cells were analyzed using two-color
and  three-color flow cytometry using a FACScan (Becton
Dickinson Co.). The analysis was repeated in triplicate per
sample.
Statistical analysis
The results were expressed as the mean ± standard
deviation (SD). The statistical analysis was performed
using the Student t-test. Differences with a P value of
less than 0.05 were considered significant.
Results and Discussion 
First of all, we investigated the percentage of broad
hematopoietic stem cells (CD34+ cells) among normal
adult PBMCs and neonatal UCBCs using an FITC-
conjugated CD34 mAb (My10) and flow cytometry with
side scattering; the gated CD34+ cells were counted. The
results are summarized in Fig. 1. As shown in Fig. 1, the
percentages of gated CD34+ cells among normal adult
PBMCs and neonatal UCBCs were 0.026 ± 0.015% and
0.365 ± 0.178%, respectively. The percentage of CD34+
cells among the neonatal UCBCs was significantly
(P<0.01) larger than that among the normal adult PBMCs.
Figure 2 shows typical histograms for the CD34+ cells
among normal adult PBMCs (panel A) and neonatal
UCBCs (panel B). The results indicated that CD34+
cells do not exist among normal adult PBMCs. Thus,
only neonatal UCBCs were used for all subsequent
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experiments in this study.
Next, we investigated the expression of CD93 on the
gated CD34+ cells from neonatal UCBCs using a PE-
conjugated CD93 mAb (mNI-11), an FITC-conjugated
CD34 mAb (My10), and two-color flow cytometry. The
results are summarized in Table 1. As shown in Table 1,
the percentage of CD93 expression on the CD34+ cells
(CD34+CD93+ cells) was 89.1%, while the percentage of
CD34+CD93¯ cells was 10.9%. Figure 3 shows typical
histograms for the CD93 expression on CD34+ cells. 
Recently, a narrow hematopoietic stem cell population,
in which the non-specific reactivity of CD34 mAb
was excluded, was identified as CD34+CD45dim+ cells.9,10)
We also investigated the percentage of CD34+CD45dim+
cells among neonatal UCBCs using an APC-conjugated
CD34 mAb (My10), a PerCP-conjugated CD45 mAb
(2D1), and two-color flow cytometry; the gated
CD34+CD45dim+ cells were counted. The results are
summarized in Table 2. As shown in Table 2, the
percentage of gated CD34+CD45dim+ cells among the
neonatal UCBCs was 0.24 ± 0.069%. Next, we
investigated the expression of CD93 on gated
CD34+CD45dim+ cells using a PE-conjugated CD93 mAb
(mNI-11) and three-color flow cytometry. The results are
summarized in Table 2. As shown in Table 2, the
percentage of CD34+CD45dim+CD93+ cells was 74.9%, while
the percentage of CD34+CD45dim+CD93¯ cells was 25.1%.
Figure 4 shows typical histograms for CD93 expression
on CD34+CD45dim+ cells.
Human CD93 has a molecular weight of about 90 –
100 kDa and is a heavily O-glycosylated type I
transmembrane protein consisting of unique C-type lectin
domains１) that exhibits a strong homology (67 – 87%
identity) with rat and mouse CD93 (C1qRp), also known
as the AA4.1 antigen.11,12) The selective expression of
CD93 myeloid cell l ineages (granulocytes and
monocytes) and endothelial cells has been reported.５) In
addition, the regulation of CD93 expression has been
investigated in a variety cells, particularly granulocytes,
and the inflammatory peptide FMLP has been shown to
upregulate the expression of this molecule rapidly.13)
Furthermore, CD93 is strongly upregulated after the
exposure of a human monocyte-like cell line (U937) to a
PKC activator, PMA, and this upregulation is controlled
by a PKC delta isoenzyme.６)
On the other hand, mouse CD93, known as the AA4.1
antigen, was found to be expressed in primitive
hematopoietic stem cells (CD34+ cells),14) suggesting that
this molecule may be involved in some important
biological functions of immune-related cells. These
findings led to the speculation regarding the possibility
that human CD93 may also be expressed on
hematopoietic stem cells similar to mouse CD93 (AA4.1
antigen). From this point of view, we investigated the
expression of CD93 on human hematopoietic stem cells
in neonatal UCBCs. As shown in this study, CD93
defined by CD93 mAb (mNI-11) was clearly expressed
in both broad and narrow hematopoietic stem cell
populations (CD34+ and CD34+CD45dim+cells, respectively)
from neonatal UCBCs. Together, these findings suggest
that human CD93 on hematopoietic stem cells may be
associated with immune biological activities, such as cell
proliferation and differentiation/maturation. 
Human immature multipotent hematopoietic
progenitor cells (hematopoietic stem cells) (CD34+ and
CD34+CD45dim+ cells) reportedly have a much higher
frequency among the UCBCs of neonates than among
normal adult PBMCs.15) In this regard, human neonatal
UCBCs have been used as a source of hematopoietic
stem cells for transplantation to enable hematopoietic
reconstitution and reduce the occurrence of acute graft-
versus-host-disease (GvHD) in recipients after
myeloablative therapy during allogenic transplantation.16,17)
Thus, the identification of these new hematopoietic stem
cell populations, CD34+CD93+ and CD34+CD45dim+CD93+cells,
among neonatal UCBCs in this study may provide
important information with potential application to the
fields of basic and clinical immunology. Recently, we
found that CD93 is also expressed on human naive T-
lymphocytes (CD4+CD45RA+ cells) among neonatal
UCBCs using a CD93 mAb (mNI-11) probe and flow
cytometry and western blot analyses.18) These results
indicate that multiple forms of CD93 exist on various
cells, particularly on immature immune-related cells, and
suggest that CD93 may be closely associated with the
development and regulation of immature cells in
neonatal immune responses, such as cell proliferation,
differentiation, maturation.
In conclusion, we have found that CD93 is expressed
on broad and narrow hematopoietic stem cell
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populations (CD34+ and CD34+CD45dim+) and that these
cell populations (CD34+CD93+ and CD34+CD45dim+CD93+cells)
exist as novel hematopoietic stem cell populations in
neonatal UCBCs. Further analyses are needed to
demonstrate the detailed properties of these cell
populations at the cellular and molecular (messenger
RNA expression of CD93) levels in both basic and
clinical fields.
References
1. Park, M., Tenner, A.J.: Cell surface expression of
C1qRP/CD93 is stabilized by O-glycosylation. J. Cell.
Physiol. 196: 512-522, 2003.
2. Tenner, A.J., Robinson, S.L., Ezekowitz, R.A.: Mannose
binding protein (MBP) enhances mononuclear
phagocyte function via a receptor that contains the
126,000 M(r) component of the C1q receptor. Immunity
3: 485-493, 1995.
3. Bohlson, S.S., Zhang, M., Ortiz, C.E., et al.: CD93
interacts with the PDZ domain-containing adaptor
protein GIPC: implications in the modulation of
phagocytosis. J. Leukoc. Biol. 77: 80-89, 2005.
4. McGreal, E.P., Ikewaki, N., Akatsu, H.,et al. : Human
C1qRp is identical with CD93 and the mNI-11
antigen but does not bind C1q. J. Immunol. 168:5222-
5232, 2002.
5. Greenlee, M.C., Sullivan, S.A., Bohlson, S.S.: CD93 and
related family members: their role in innate
immunity. Curr. Drug Targets 9: 130-138, 2008.
6. Ikewaki, N., Kulski, J.K., Inoko, H.: Regulation of
CD93 cell surface expression by protein kinase C
isoenzymes. Microbiol. Immunol. 50: 93-103, 2006. 
7. Maruyama, H., Galvan, M., Waffarn, F., et al.: Human
cord blood leukocyte innate immune responses to
defense collagens. Pediatr. Res. 54: 724-731, 2003.
8. Ikewaki, N. , Inoko, H. : Development and
characterization of a novel monoclonal antibody
(mNI-11) that induces cell adhesion of the LPS-
stimulated human monocyte-like cell line U937. J.
Leukoc. Biol. 59: 697-708, 1996.
9. Pallis, M., Syan, J., Russell, N.H. : Flow cytometric
chemosensitivity analysis of blasts from patients
with acute myeloblastic leukemia and
myelodysplastic syndromes: the use of 7AAD with
antibodies to CD45 or CD34. Cytometry 37: 308-313,
1999.
10. Brocklebank, A.M., Sparrow, R.L.: Enumeration of
CD34+ cells in cord blood: a variation on a single-
platform flow cytometric method based on the
ISHAGE gating strategy. Cytometry 46: 254-261,
2001.
11. Dean, Y. D., McGreal, E. P., Akatsu, H. et al.: Molecular
and cellular properties of the rat AA4 antigen, a C-
type lectin-like receptor with structural homology to
thrombomodulin. J. Biol. Chem. 275: 34382-34392,
2000.
12. Dean, Y. D., McGreal, E.P., Gasque, P.: Endothelial
cells, megakaryoblasts, platelets and alveolar
epithelial cells express abundant levels of the mouse
AA4 antigen, a C-type lectin-like receptor involved in
homing activities and innate immune host defense.
Eur. J. Immunol. 31: 1370-1381, 2001.
13. Jack, R.M., Lowenstein, B.A., Nicholson-Weller, A.:
Regulation of C1q receptor expression on human
polymorphonuclear leukocytes. J. Immunol. 153:262-
269, 1994.
14. Yamane, T. , Hosen, N. , Yamazaki, H. , et al . :
Expression of AA4.1 marks lymphohematopoietic
progenitors in early mouse development. Proc. Natl.
Acad. Sci. U. S. A. 106: 8953-8958, 2009. 
15. Ruhil, S., Kumar, V., Rathee. P.: Umbilical cord stem
cell: an overview. Curr. Pharm. Biotechnol. 10:327-
334, 2009.
16. Brown, J.A., Boussiotis, V.A.: Umbilical cord blood
transplantation: basic biology and clinical challenges
to immune reconstitution. Clin. Immunol. 127: 286-
297, 2008.
17. Kurtzberg, J. : Update on umbilical cord blood
transplantation. Curr. Opin. Pediatr. 21:22-29, 2009.
18. Ikewaki, N., Yamao, H., Kulski, J.K, et al.: Flow
cytometric identification of CD93 expression on
naive T lymphocytes (CD4(+)CD45RA (+) cells) in
human neonatal umbilical cord blood. J . Clin.
Immunol. 30: 723-733, 2010. 
105Nobunao IKEWAKI et al：Identification of CD93 expression on hematopoietic stem cells 
Donor CD34+ (%) CD34+CD93+ (%) CD34+CD93- (%) 
1
2
3
4
5
6
7
8
9
10
11
0.38
0.30
0.23
0.29
0.30
0.34
0.83
0.25
0.40
0.51
0.18
87.3
60.8
91.4
91.8
92.0
94.2
88.3
96.8
95.9
91.5
89.0
12.7
39.2
8.6
8.2
8.0
5.8
11.7
3.2
4.1
8.5
11.0
The neonatal UCBCs (n=11) were incubated with an FITC-conjugated CD34 mAb (My10) and a PE-conjugated CD93 mAb
(mNI-11) for 40 min at room temperature. Negative controls were incubated with isotype-matched normal mouse IgG1.
The percentages of positively stained cells were determined using two-color flow cytometry. The analysis was repeated
in triplicate per sample
Table1. Percentages of CD93 expression on CD34+ cells in neonatal UCBCs
Table 2.  Percentages of CD93 expression on CD34+CD45dim+ cells in neonatal UCBCs
1
2
3
4
5
6
Donor CD34+CD45dim+ (%) CD34+CD45dim+CD93+ (%) CD34+CD45dim+CD93- (%) 
0.23
0.12
0.33
0.27
0.26
0.23
84.9
59.9
82.9
54.7
86.9
80.6
15.1
40.1
17.1
45.3
13.1
19.4
The neonatal UCBCs (n=6) were incubated with an APC-conjugated CD34 mAb (My10), a PerCP-conjugated CD45 mAb
(2D1), and a PE-conjugated CD93 mAb (mNI-11) for 40 min at room temperature. Negative controls were incubated with
isotype-matched normal mouse IgG1. The percentages of positively stained cells were determined using three-color flow
cytometry. The analysis was repeated in triplicate per sample.
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Figure 1. Percentages of CD34+ cells among normal adult PBMCs and neonatal UCBCs. Normal adult PBMCs (n=4) and
neonatal UCBCs (n=11) were incubated with an FITC-conjugated CD34 mAb (My10) for 40 min at room temperature.
Negative controls were incubated with isotype-matched normal mouse IgG1. The percentages of positively stained CD34+
cells were determined using CD34 mAb and flow cytometry with side scattering; the gated CD34+ cells were counted. The
analysis was repeated in triplicate per sample. P<0.01 (CD34+ cells of neonatal UCBCs vs. CD34+ cells of adult PBMCs). 
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Figure 2. Typical flow cytometric histograms of CD34+ cells in normal adult PBMCs and neonatal UCBCs. The normal adult
PBMCs (panel A) and neonatal UCBCs (panel B) were incubated with an FITC-conjugated CD34 mAb (My10) for 40 min at
room temperature. The percentage of CD34+ cells among these cells was analyzed using CD34 mAb (My10) and flow
cytometry with side scattering; the gated CD34+ cells were counted. Negative controls were incubated with isotype-matched
normal mouse IgG1. The analysis was repeated in triplicate per sample.
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Figure 3. Typical flow cytometric histograms of CD93 expression on CD34+ cells from neonatal UCBCs. The neonatal UCBCs
cells were incubated with an FITC-conjugated CD34 mAb (My10) and a PE-conjugated CD93 mAb (mNI-11) for 40 min at
room temperature. Negative controls were incubated with isotype-matched normal mouse IgG1. The percentages of positively
stained cells were determined using two-color flow cytometry. The analysis was repeated in triplicate per sample.
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Figure 4. Typical flow cytometric histograms of CD93 expression on CD34+CD45dim+ cells from neonatal UCBCs. The neonatal
UCBCs were incubated with an APC-conjugated CD34 mAb (My10), a PerCP-conjugated CD45 mAb (2D1), and a PE-
conjugated CD93 mAb (mNI-11) for 40 min at room temperature. Negative controls were incubated with isotype-matched
normal mouse IgG1. The percentages of positively stained cells were determined using three-color flow cytometry. The
analysis was repeated in triplicate per sample.
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臍帯血由来造血幹細胞表面上のCD93の発現
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＊*＊東海大学医学部分子生命学　〒259-1193 神奈川県伊勢原市下糟屋143
要旨
臍帯血由来造血幹細胞表面上のCD93の発現を我々が開発したCD93モノクローナル抗体(mNI-11)、
既存のCD34抗体、CD45抗体を組み合わせたフローサイトメトリー法で解析した。その結果、臍帯
血由来造血幹細胞（CD34+細胞およびCD34+CD45dim+細胞）表面上にはCD93が発現していることが
分かった。以上の結果は、CD93が未熟な造血幹細胞の新たな細胞表面マーカーに成り得ると共に、
造血幹細胞におけるCD93の免疫学的な機能解析に非常に有益な情報と考えられる。
キーワード：CD93 フローサイトメトリー解析　造血幹細胞　臍帯血細胞
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